These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12742465)

  • 21. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunosuppression with sirolimus so donor kidneys survive longer].
    MMW Fortschr Med; 2004 Aug; 146(31-32):46-7. PubMed ID: 15529711
    [No Abstract]   [Full Text] [Related]  

  • 23. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience.
    El-Sabrout R; Delaney V; Qadir M; Butt F; Hanson P; Butt KM
    Transplant Proc; 2003 May; 35(3 Suppl):89S-94S. PubMed ID: 12742474
    [No Abstract]   [Full Text] [Related]  

  • 24. Steroid immunosuppression in kidney transplantation: a passing era.
    Schulak JA
    J Surg Res; 2004 Mar; 117(1):154-62. PubMed ID: 15013726
    [No Abstract]   [Full Text] [Related]  

  • 25. Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.
    Langer RM; Hong DM; Katz SM; Van Buren CT
    Transplant Proc; 2002 Dec; 34(8):3162-4. PubMed ID: 12493406
    [No Abstract]   [Full Text] [Related]  

  • 26. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts.
    Youseff N; Small S
    Transplant Proc; 2002 Aug; 34(5):1653-5. PubMed ID: 12176522
    [No Abstract]   [Full Text] [Related]  

  • 28. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 29. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
    Vincenti F; Stock P
    Transplant Proc; 2003 May; 35(3 Suppl):183S-186S. PubMed ID: 12742494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Toward an evidence-based immunosuppression].
    Pascual J
    Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
    [No Abstract]   [Full Text] [Related]  

  • 31. Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study.
    Charpentier B; Groth CG; Bäckman L; Morales JM; Calne R; Kreis H; Lang P; Touraine JL; Claesson K; Campistol JM; Durand D; Wramner L; Brattström C;
    Transplant Proc; 2003 May; 35(3 Suppl):58S-61S. PubMed ID: 12742468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA; Heizer KE
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of Certican (everolimus, rad) in the many pathways of chronic rejection.
    Nashan B
    Transplant Proc; 2001; 33(7-8):3215-20. PubMed ID: 11750380
    [No Abstract]   [Full Text] [Related]  

  • 34. Minimizing calcineurin inhibitor drugs in renal transplantation.
    Flechner SM
    Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of sirolimus to facilitate cyclosporine avoidance or steroid withdrawal in kidney transplant recipients.
    Hricik DE
    Transplant Proc; 2003 May; 35(3 Suppl):73S-78S. PubMed ID: 12742471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of sirolimus in kidney transplantation.
    Podbielski J; Schoenberg L
    Prog Transplant; 2001 Mar; 11(1):29-32. PubMed ID: 11357554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations].
    Arns W; Budde K; Eitner F; Gwinner W; Hugo C; Pressmar K; Weimann A; Witzke O
    Dtsch Med Wochenschr; 2011 Dec; 136(49):2554-9. PubMed ID: 22131077
    [No Abstract]   [Full Text] [Related]  

  • 40. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients.
    El-Sabrout R; Weiss R; Butt F; Delaney V; Qadir M; Hanson P; Butt K
    Transplant Proc; 2002 Aug; 34(5):1942-3. PubMed ID: 12176636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.